Starpharma Holdings Limited (SPL) - Financial and Strategic SWOT Analysis Review

Date: November 24, 2015
Pages: 44
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S9AA2A8347BEN
Leaflet:

Download PDF Leaflet

Starpharma Holdings Limited (SPL) - Financial and Strategic SWOT Analysis Review
Starpharma Holdings Limited (SPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Starpharma Holdings Limited (Starpharma) develops dendrimer products for pharmaceutical, life science and other applications. It has three development programs namely, VivaGel portfolio, drug delivery and agrochemicals. The company also markets its products through license arrangements with partners such as Siemens Healthcare and Merck KgaA, among others. Its flagship product VivaGel (under clinical development) is a gel-based formulation of a proprietary dendrimer for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma’s research facilities are located in Melbourne, Australia. It is headquartered in Melbourne, Australia.

Starpharma Holdings Limited Key Recent Developments

Nov 11, 2013: Starpharma new Board appointment
Aug 26, 2013: Starpharma holdings preliminary financial report year ended 30 June 2013
Jul 17, 2013: Starpharma appoints Business Development executive
Jul 11, 2013: ARC grant for Starpharma's targeted drug delivery
Jul 11, 2013: ARC grant for Starpharma's targeted drug delivery

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Starpharma Holdings Limited - Key Facts
Starpharma Holdings Limited - Key Employees
Starpharma Holdings Limited - Key Employee Biographies
Starpharma Holdings Limited - Major Products and Services
Starpharma Holdings Limited - Pharmaceutical Pipeline Products Data
Starpharma Holdings Limited, Pipeline Products by Therapy Area
Starpharma Holdings Limited, Pipeline Products by Development Phase
Starpharma Holdings Limited - History
Starpharma Holdings Limited - Company Statement
Starpharma Holdings Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Starpharma Holdings Limited - Business Description
Starpharma Holdings Limited - Corporate Strategy
Starpharma Holdings Limited - SWOT Analysis
SWOT Analysis - Overview
Starpharma Holdings Limited - Strengths
Strength - Business Collaborations
Strength - Proprietary Technology
Starpharma Holdings Limited - Weaknesses
Weakness - Weak Financial Performance
Starpharma Holdings Limited - Opportunities
Opportunity - Emerging Markets
Opportunity - Focus on Treatment of Bacterial Vaginosis
Opportunity - Market Potential: HIV
Starpharma Holdings Limited - Threats
Threat - Government Regulations
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Starpharma Holdings Limited - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Starpharma Holdings Limited, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 29, 2014: Starpharma Receives $4.2 million R&D Tax Incentive Refund
Aug 13, 2014: Starpharma Holdings announces Annual Report and full year financial results
Jun 13, 2014: Rob Thomas succeeds retiring Chairman Peter Bartels
Apr 07, 2014: Starpharma expands its Drug Delivery Program with AstraZeneca
Mar 11, 2014: Starpharma receives $4.7M R&D tax incentives
Feb 24, 2014: Starpharma Interim Report and Half-year Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer 44

LIST OF TABLES

Starpharma Holdings Limited, Key Facts
Starpharma Holdings Limited, Key Employees
Starpharma Holdings Limited, Key Employee Biographies
Starpharma Holdings Limited, Major Products and Services
Starpharma Holdings Limited, Number of Pipeline Products by Therapy Area
Starpharma Holdings Limited, Number of Pipeline Products by Development Stage
Starpharma Holdings Limited, Pipeline Products By Therapy Area and Development Phase
Starpharma Holdings Limited, History
Starpharma Holdings Limited, Subsidiaries
Starpharma Holdings Limited, Key Competitors
Starpharma Holdings Limited, Ratios based on current share price
Starpharma Holdings Limited, Annual Ratios
Starpharma Holdings Limited, Interim Ratios
Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Starpharma Holdings Limited, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios 43

LIST OF FIGURES

Starpharma Holdings Limited, Pipeline Products by Therapy Area
Starpharma Holdings Limited, Pipeline Products by Development Phase
Starpharma Holdings Limited, Performance Chart (2011 - 2015)
Starpharma Holdings Limited, Ratio Charts
Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Starpharma Holdings Limited, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Skip to top


Ask Your Question

Starpharma Holdings Limited (SPL) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: